UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)

European heart journal, 2013-05, Vol.34 (20), p.1498-1505

2013

Volltextzugriff (PDF)

A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)

Thrombosis and haemostasis, 2009-01, Vol.101 (1), p.68-76

2009

Volltextzugriff (PDF)

Recommendation of mavacamten posology by model‐based analyses in adults with obstructive hypertrophic cardiomyopathy

CPT: pharmacometrics and systems pharmacology, 2024-09, Vol.13 (9), p.1448-1461

2024

Volltextzugriff (PDF)

Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration

CPT: pharmacometrics and systems pharmacology, 2024-09, Vol.13 (9), p.1462-1475

2024

Volltextzugriff (PDF)

Platelet Glycoprotein IIb-IIIa Antagonists as Prototypical Integrin Blockers: Novel Parenteral and Potential Oral Antithrombotic Agents

Journal of medicinal chemistry, 2000-09, Vol.43 (19), p.3453-3473

2000

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease

British journal of clinical pharmacology, 2019-06, Vol.85 (6), p.1290-1302

2019

Volltextzugriff (PDF)

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12 -receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)

The American heart journal, 2010-07, Vol.160 (1), p.65-72

2010

Volltextzugriff (PDF)

Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trial

The American heart journal, 2009-12, Vol.158 (6), p.998-1004.e1

2009

Volltextzugriff (PDF)

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease

Blood, 2019-04, Vol.133 (17), p.1865-1875

2019

Volltextzugriff (PDF)

Drug-Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model

Journal of clinical pharmacology, 2023-11, Vol.63 (11), p.1275-1282

2023

Volltextzugriff (PDF)

Effects of Omeprazole and Verapamil on the Pharmacokinetics, Safety, and Tolerability of Mavacamten: Two Drug–Drug Interaction Studies in Healthy Participants

Clinical pharmacology in drug development, 2023-12, Vol.12 (12), p.1241-1251

2023

Volltextzugriff (PDF)

Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients

The American heart journal, 2010-04, Vol.159 (4), p.508-517.e1

2010

Volltextzugriff (PDF)

PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers

Journal of clinical pharmacology, 2017-02, Vol.57 (2), p.194-210

2017

Volltextzugriff (PDF)

The Kinetics of Integrilin Limited by Obesity: A multicenter randomized pharmacokinetic and pharmacodynamic clinical trial

The American heart journal, 2011-12, Vol.162 (6), p.996-1002

2011

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic properties of eptifibatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin

Clinical therapeutics, 2003-10, Vol.25 (10), p.2564-2574

GRETLER, Daniel D

2003

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function

Clinical therapeutics, 2004, Vol.26 (3), p.390-398

2004

Volltextzugriff (PDF)

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)

The American heart journal, 2010-07, Vol.160 (1), p.65-72

2010

Volltextzugriff (PDF)

The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to cyp 2c192 genotype: first experience in patients

Journal of thrombosis and haemostasis, 2010-01, Vol.8 (1), p.43-53

2010

Volltextzugriff (PDF)

Noninvasive method for determination of arterial compliance using Doppler echocardiography and subclavian pulse tracings : validation and clinical application of a physiological model of the circulation

Circulation (New York, N.Y.), 1994-06, Vol.89 (6), p.2688-2699

1994

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin

Clinical therapeutics, 2003-10, Vol.25 (10), p.2564-2574

Gretler, Daniel D.

2003

Volltextzugriff (PDF)

P2290Physiologically-based pharmacokinetic (PBPK) model predicted versus observed effect of Child Pugh mild and moderate hepatic impairment on betrixaban pharmacokinetics

European heart journal, 2018-08, Vol.39 (suppl_1)

2018

Volltextzugriff (PDF)

ABSENCE OF QTC PROLONGATION WITH BETRIXABAN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND POSITIVE-CONTROLLED THOROUGH ECG STUDY

Journal of the American College of Cardiology, 2013-03, Vol.61 (10), p.E271-E271

2013

Volltextzugriff (PDF)

Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study

Expert opinion on pharmacotherapy, 2013-01, Vol.14 (1), p.5-13

2013

Volltextzugriff (PDF)

Platelet functions beyond hemostasis

Journal of thrombosis and haemostasis, 2009-11, Vol.7 (11), p.1759-1766

2009

Volltextzugriff (PDF)

Ethnic Differences in Circadian Hemodynamic Profile

American journal of hypertension, 1994-01, Vol.7 (1), p.7-14

1994

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(48)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(34)
Humans
(29)
Male
(24)
Female
(22)
Middle Aged
(21)
Biological And Medical Sciences
(20)
Medical Sciences
(18)
Cardiovascular System & Cardiology
(17)
Adult
(14)
Aged
(13)
Pharmacology & Pharmacy
(12)
Cardiac & Cardiovascular Systems
(11)
Peripheral Vascular Disease
(11)
Pharmacology. Drug Treatments
(11)
Double-Blind Method
(8)
Pharmacokinetics
(8)
Administration, Oral
(7)
Drug Dosages
(7)
Blood. Blood Coagulation. Reticuloendothelial System
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)

A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)

Recommendation of mavacamten posology by model‐based analyses in adults with obstructive hypertrophic cardiomyopathy

Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration

Platelet Glycoprotein IIb-IIIa Antagonists as Prototypical Integrin Blockers: Novel Parenteral and Potential Oral Antithrombotic Agents

Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12 -receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease

Drug-Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model

Effects of Omeprazole and Verapamil on the Pharmacokinetics, Safety, and Tolerability of Mavacamten: Two Drug–Drug Interaction Studies in Healthy Participants

Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients

PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers

The Kinetics of Integrilin Limited by Obesity: A multicenter randomized pharmacokinetic and pharmacodynamic clinical trial

Pharmacokinetic and pharmacodynamic properties of eptifibatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin

Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function

The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to cyp 2c192 genotype: first experience in patients

Noninvasive method for determination of arterial compliance using Doppler echocardiography and subclavian pulse tracings : validation and clinical application of a physiological model of the circulation

Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin

P2290Physiologically-based pharmacokinetic (PBPK) model predicted versus observed effect of Child Pugh mild and moderate hepatic impairment on betrixaban pharmacokinetics

ABSENCE OF QTC PROLONGATION WITH BETRIXABAN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND POSITIVE-CONTROLLED THOROUGH ECG STUDY

Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study

Platelet functions beyond hemostasis

Ethnic Differences in Circadian Hemodynamic Profile

Suchergebnisse filtern